1315 Capital and Ampersand Capital Partners Invest $20M in Interpace Biosciences
January 13, 2020
Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.
- Buyers
- 1315 Capital, Ampersand Capital Partners
- Targets
- Interpace Biosciences, Inc.
- Industry
- Healthcare Services
- Location
- New Jersey, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Ampersand Capital Partners Invests in AnaBios Corporation
June 7, 2022
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.
-
Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business
July 15, 2019
Healthcare Services
Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.
-
Ampersand Capital Partners Acquires Biologos LLC
March 19, 2024
Biotechnology
Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.
-
Flagship Biosciences Acquires Interpace Pharma Solutions from Interpace Biosciences
September 1, 2022
Healthcare Services
Flagship Biosciences has acquired Interpace Pharma Solutions (IPS), a division of Interpace Biosciences, expanding Flagship's molecular pathology, cytogenetics, genomics and biomarker analytics capabilities. The deal follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies and adds a state-of-the-art laboratory in Research Triangle Park, North Carolina to Flagship's service offering.
-
Ampersand Capital Partners Invests in BioEcho Life Sciences
March 1, 2022
Biotechnology
Ampersand Capital Partners made a minority growth equity investment in Cologne-based BioEcho Life Sciences to support the company's global expansion, new product launches, and expansion of its direct salesforce. As part of the transaction Ampersand appointed Frank Witney and Arya Mehrabanzad to BioEcho's board; financial terms were not disclosed.
-
Ampersand Capital Partners Invests in Alliance Pharma
November 18, 2021
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.